Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways

Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers. However, its efficacy in esophageal cancer remains unclear. In this study, we found that the high expression of HDAC6 was associated with poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Jinlin, Lv, Wang, Wang, Luming, Xu, Jinming, Yuan, Ping, Huang, Sha, He, Zhehao, Hu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062526/
https://www.ncbi.nlm.nih.gov/pubmed/30050135
http://dx.doi.org/10.1038/s41419-018-0788-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062526/
https://www.ncbi.nlm.nih.gov/pubmed/30050135
http://dx.doi.org/10.1038/s41419-018-0788-2

Ejemplares similares